Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directors

Prof. June is a world authority on immune tolerance and adoptive immunotherapy

Appointment reaffirms AC Immune’s scientific leadership in neurodegeneration

LAUSANNE, Switzerland, Nov. 20, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Prof. Carl H. June, a world authority on mechanisms related to immune tolerance and adoptive immunotherapy in the fields of chronic inflammation and cancer, was elected to the Company’s Board of Directors, at an extraordinary shareholders’ meeting today.

Prof. June is a true pioneer in the field of immunotherapy most well-known for his research into T cell therapies for the treatment of cancer, who, in 2020, was elected to the American Philosophical Society. His expertise can further accelerate AC Immune’s progress in advancing its pipeline of immunotherapies and therapies targeting neuroinflammation.

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “We welcome Prof. June’s timely appointment, as neurodegeneration is increasingly linked to inflammatory mechanisms, a key scientific focus for AC Immune’s discovery efforts. His appointment is a further affirmation of our scientific leadership in the neurodegenerative disease field. Prof. June’s significant expertise and standing in the scientific community will be an invaluable asset as we work to develop innovative immunotherapies and target neuroinflammation using our proprietary technology platforms.”

Prof. June commented: “I am proud to be invited to join the Board of Directors of AC Immune, an established pioneer at the forefront of discovering and developing treatments for neurodegenerative diseases. It is tremendously exciting to be involved at the cutting edge of research addressing an area with such a high unmet medical need, where immunotherapy and inflammation could play a critically important role. I look forward to working with the outstanding team at AC Immune and hope my own expertise will contribute to their continued success.”

Prof. June is Richard W. Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania. Due to his lifelong work on lymphocyte activation, Prof. June is considered a world authority on mechanisms related to immune tolerance and adoptive immunotherapy in the fields of chronic inflammation and cancer. He and his team pioneered the groundbreaking work in immunotherapy in which patients with refractory and relapsed chronic lymphocytic leukemia are treated with genetically engineered versions of their own T cells. This CAR-T therapy approach, which trains the immune system to attack and destroy cancer cells, has opened a new era of innovative treatments and personalized medicine for cancer patients.